Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Titel:
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Auteur:
Alistar, Angela Morris, Bonny B Desnoyer, Rodwige Klepin, Heidi D Hosseinzadeh, Keyanoosh Clark, Clancy Cameron, Amy Leyendecker, John D'Agostino Jr, Ralph Topaloglu, Umit Boteju, Lakmal W Boteju, Asela R Shorr, Rob Zachar, Zuzana Bingham, Paul M Ahmed, Tamjeed Crane, Sandrine Shah, Riddhishkumar Migliano, John J Pardee, Timothy S Miller, Lance Hawkins, Gregory Jin, Guangxu Zhang, Wei Pasche, Boris